phrykt

Jazz Pharmaceuticals plc (JAZZ): who owns it and who trades it

As of Nov 16, 2026, JAZZ insiders reported 67 open-market sales worth $87.9M and no purchases in the last 12 months, with 40% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bruce C Cozadd (Director), with $45.3M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Jazz Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns JAZZ

641 funds and institutions reported JAZZ shares worth $15.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.5%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.9.5%
FMR LLC (Fidelity)7.3%
Vanguard Portfolio Management LLC4.8%
Vanguard Capital Management LLC4.4%
Capital World Investors4.3%
Lsv Asset Management3.6%
Franklin Resources Inc3.3%
State Street Corp3.2%
Dimensional Fund Advisors LP2.7%
Fuller & Thaler Asset Management, Inc.2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.97M9.51%$1.4B+7%
FMR LLC (Fidelity)4.61M7.35%$1.1B+103%
Vanguard Portfolio Management LLC3.04M4.84%$732M+2%
Vanguard Capital Management LLC2.73M4.35%$658M+3%
Capital World Investors2.70M4.30%$650M+1%
Lsv Asset Management2.28M3.63%$548M-5%
Franklin Resources Inc2.04M3.25%$492M+4%
State Street Corp2.00M3.19%$482M+6%
Dimensional Fund Advisors LP1.71M2.73%$413M-10%
Fuller & Thaler Asset Management, Inc.1.64M2.61%$395M-2%
Bank of New York Mellon Corp1.58M2.52%$380M-6%
AQR Capital Management LLC1.52M2.43%$360M+14%
Geode Capital Management, LLC1.48M2.36%$357M+20%
Ameriprise Financial Inc1.22M1.94%$293M-24%
JPMorgan Chase & Co1.16M1.85%$277M–
Bank of America Corp1.14M1.81%$274M+12%
Citadel Advisors LLC1.01M1.60%$243M-20%
Swedbank AB968,0921.54%$233M-2%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.799,2971.27%$193M-10%
Millennium Management LLC763,8801.22%$184M-39%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, JAZZ insiders reported $0 of open-market purchases and $87.9M of sales. 40% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$87.9M
67 trades, 11 people
Sales under a 10b5-1 plan
40%
Share of sale value
Latest trade
Nov 6, 2026
Filed Nov 10, 2026

Purchases and sales by month

$20.7M$20.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 6, 2026Bruce C CozaddDirectorSale27,714$234.91$6.5MForm 4
Nov 6, 2026Bruce C CozaddDirectorSale10,688$235.82$2.5MForm 4
Nov 6, 2026Bruce C CozaddDirectorSale24,483$236.84$5.8MForm 4
Nov 6, 2026Bruce C CozaddDirectorSale5,923$237.39$1.4MForm 4
Nov 4, 2026Patricia CarrVice presidentSale1,250$231.37$289KForm 4
Nov 4, 2026Patricia CarrVice presidentSale163$231.27$37.7KForm 4
Nov 3, 2026Renee D GalaCEOSale plan1,000$225.37$225KForm 4
Nov 2, 2026Bruce C CozaddDirectorSale plan6,000$215.84$1.3MForm 4
Oct 6, 2026Renee D GalaCEOSale plan2,000$236.40$473KForm 4
Oct 1, 2026Bruce C CozaddDirectorSale plan6,000$230.33$1.4MForm 4
Sep 10, 2026Neena M PatilVice presidentSale plan1,200$240.94$289KForm 4
Sep 8, 2026Renee D GalaCEOSale plan2,000$243.03$486KForm 4
Sep 1, 2026Bruce C CozaddDirectorSale plan6,000$250.13$1.5MForm 4
Aug 27, 2026Robert IannoneVice presidentSale plan18,187$247.86$4.5MForm 4
Aug 27, 2026Robert IannoneVice presidentSale plan11,423$248.67$2.8MForm 4
Aug 27, 2026Robert IannoneVice presidentSale plan18,113$250.02$4.5MForm 4
Aug 27, 2026Robert IannoneVice presidentSale plan9,259$251.95$2.3MForm 4
Aug 27, 2026Robert IannoneVice presidentSale plan300$252.76$75.8KForm 4
Aug 27, 2026Robert IannoneVice presidentSale plan19,639$250.60$4.9MForm 4
Aug 3, 2026Bruce C CozaddDirectorSale plan6,000$252.98$1.5MForm 4
Jul 1, 2026Bruce C CozaddDirectorSale plan6,000$240.47$1.4MForm 4
Jun 15, 2026Mark Douglas SmithDirectorSale plan1,157$230.55$267KForm 4
Jun 10, 2026Neena M PatilVice presidentSale plan1,200$231.83$278KForm 4
Jun 1, 2026Bruce C CozaddDirectorSale plan6,000$235.12$1.4MForm 4
May 28, 2026Neena M PatilVice presidentSale plan1,192$236.97$282KForm 4
May 28, 2026Samantha PearceVice presidentSale6,907$235.41$1.6MForm 4
May 22, 2026Rick E WinninghamDirectorSale2,741$241.57$662KForm 4
May 22, 2026Heather Ann McSharryDirectorSale2,000$241.00$482KForm 4
May 1, 2026Bruce C CozaddDirectorSale plan6,000$203.33$1.2MForm 4
Apr 1, 2026Bruce C CozaddDirectorSale plan2,292$190.94$438KForm 4
Apr 1, 2026Bruce C CozaddDirectorSale plan3,684$190.22$701KForm 4
Apr 1, 2026Bruce C CozaddDirectorSale plan24$191.74$4.6KForm 4
Mar 9, 2026Patricia CarrVice presidentSale1,287$182.94$235KForm 4
Mar 3, 2026Bruce C CozaddDirectorSale plan3,159$186.09$588KForm 4
Mar 3, 2026Bruce C CozaddDirectorSale plan2,608$186.73$487KForm 4
Mar 3, 2026Bruce C CozaddDirectorSale plan233$187.84$43.8KForm 4
Feb 27, 2026Norbert G RiedelDirectorSale3,415$192.00$656KForm 4
Feb 27, 2026Patricia CarrVice presidentSale1,117$190.91$213KForm 4
Feb 26, 2026Patricia CarrVice presidentSale1,253$194.11$243KForm 4
Feb 26, 2026Neena M PatilVice presidentSale875$192.07$168KForm 4
Feb 26, 2026Neena M PatilVice presidentSale15,555$190.28$3MForm 4
Feb 26, 2026Neena M PatilVice presidentSale2,916$189.81$553KForm 4
Feb 26, 2026Neena M PatilVice presidentSale11,529$191.65$2.2MForm 4
Feb 26, 2026Neena M PatilVice presidentSale3,523$193.58$682KForm 4
Feb 26, 2026Neena M PatilVice presidentSale1,061$190.00$202KForm 4
Feb 26, 2026Neena M PatilVice presidentSale549$190.80$105KForm 4
Feb 26, 2026Neena M PatilVice presidentSale1,784$191.88$342KForm 4
Feb 26, 2026Neena M PatilVice presidentSale1,009$192.79$195KForm 4
Feb 26, 2026Neena M PatilVice presidentSale197$193.60$38.1KForm 4
Feb 26, 2026Neena M PatilVice presidentSale16,602$192.53$3.2MForm 4
Feb 26, 2026Mary Elizabeth HendersonVice presidentSale5,343$194.49$1MForm 4
Dec 9, 2025Mary Elizabeth HendersonVice presidentSale2,238$169.51$379KForm 4
Dec 5, 2025Patricia CarrVice presidentSale160$171.11$27.4KForm 4
Dec 5, 2025Patricia CarrVice presidentSale4,500$171.20$770KForm 4
Nov 26, 2025Bruce C CozaddDirectorSale507$179.79$91.2KForm 4
Nov 26, 2025Bruce C CozaddDirectorSale38,126$177.27$6.8MForm 4
Nov 26, 2025Bruce C CozaddDirectorSale30,487$178.06$5.4MForm 4
Nov 26, 2025Bruce C CozaddDirectorSale8,380$179.23$1.5MForm 4
Nov 20, 2025Heather Ann McSharryDirectorSale3,415$177.78$607KForm 4
Nov 18, 2025Bruce C CozaddDirectorSale3,384$180.09$609KForm 4
Nov 18, 2025Bruce C CozaddDirectorSale5,517$181.81$1MForm 4
Nov 18, 2025Bruce C CozaddDirectorSale717$182.60$131KForm 4
Nov 18, 2025Bruce C CozaddDirectorSale8,382$180.88$1.5MForm 4
Nov 18, 2025Patricia CarrVice presidentSale69$181.66$12.5KForm 4
Nov 18, 2025Patricia CarrVice presidentSale5,250$182.07$956KForm 4
Nov 18, 2025Rick E WinninghamDirectorSale5,500$180.86$995KForm 4
Nov 17, 2025Robert IannoneVice presidentSale plan7,159$168.26$1.2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Bruce C CozaddDirector–$45.3MNov 6, 2026
Robert IannoneEVP, Global Head of R&D & CMO–$20.4MAug 27, 2026
Neena M PatilEVP & Chief Legal Officer–$11.5MSep 10, 2026
Patricia CarrSVP, Chief Accounting Officer–$2.8MNov 4, 2026
Rick E WinninghamDirector–$1.7MMay 22, 2026
Samantha PearceEVP, Chief Commercial Officer–$1.6MMay 28, 2026
Mary Elizabeth HendersonSVP, Technical Operations–$1.4MFeb 26, 2026
Renee D GalaPresident & CEO–$1.2MNov 3, 2026
Heather Ann McSharryDirector–$1.1MMay 22, 2026
Norbert G RiedelDirector–$656KFeb 27, 2026
Mark Douglas SmithDirector–$267KJun 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

JAZZ short interest

Moderate short interest. 9.0% of JAZZ shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 20%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.80M JAZZ shares were sold short, 9.0% of the shares outstanding, down 1.1% from the report before. At the average daily volume of 755,707 shares, buying them all back would take about 7.7 trading days (days to cover).

Shares short, % of all shares

9.03%May 15Oct 309.61%

Days to cover

7.7May 15Oct 308.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.80M9.03%-1%755,7077.7
Oct 15, 20265.86M9.03%+7%854,8076.9
Sep 30, 20265.48M8.44%+17%845,8096.5
Sep 15, 20264.68M7.20%+1%647,8777.2
Aug 31, 20264.62M7.12%+28%1.26M3.7
Aug 14, 20263.61M5.57%+8%949,5493.8
Jul 31, 20263.36M5.17%-12%629,7815.3
Jul 15, 20263.80M6.06%+9%786,5954.8
Jun 30, 20263.50M5.58%-11%932,5403.8
Jun 15, 20263.94M6.28%-8%930,0914.2
May 29, 20264.29M6.84%-12%842,4675.1
May 15, 20264.85M7.73%-5%1.03M4.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Jazz Pharmaceuticals company events

Jazz Pharmaceuticals filed 16 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026ResultsReleased financial results. Filing
  2. Oct 26, 2026ResultsReleased financial results. Filing
  3. Oct 9, 2026LeadershipSamantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027. Filing
  4. Sep 23, 2026AgreementFor the purpose of extending the maturity date and repricing the outstanding U.S. dollar term loan B-2 facility incurred on July 19, 2024, on September 23, 2026, Jazz Financing Lux S.à r.l., a private limited liability company ( société à responsabilité limitée ) incorporated and existing under the… Filing
  5. Sep 15, 2026AnnouncementShared information with investors. Filing
  6. Aug 31, 2026AgreementJazz Investments I Limited, a Bermuda exempted company limited by shares and a wholly-owned subsidiary of Jazz Pharmaceuticals plc, completed its previously announced private offering of $1.25 billion of its 1.875% exchangeable senior notes due 2032, which amount includes the exercise in full by… Filing
  7. Aug 25, 2026AnnouncementJazz Pharmaceuticals plc issued a press release announcing that the U.S. Food and Drug Administration approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal… Filing
  8. Aug 10, 2026AgreementJazz Pharmaceuticals, Inc., a wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company, entered into an Agreement and Plan of Merger with Knight Acquisition Corp., a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, Actio Biosciences, Inc., a Delaware… Filing
  9. Aug 10, 2026AnnouncementShared information with investors. Filing
  10. Aug 3, 2026ResultsReleased financial results. Filing
  11. Jul 24, 2026VoteReported shareholder vote results. Filing
  12. May 29, 2026LeadershipAnne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc 2026 annual meeting of shareholders, has informed the board of directors that she will not stand for re-election. Filing
  13. May 5, 2026ResultsReleased financial results. Filing
  14. Feb 24, 2026ResultsReleased financial results. Filing
  15. Jan 12, 2026ResultsReleased financial results. Filing
  16. Nov 17, 2025AnnouncementJazz Pharmaceuticals plc issued a press release announcing positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera ® (zanidatamab-hrii) in combination with chemotherapy, and with or without the checkpoint inhibitor tislelizumab, as a first-line treatment for HER2-positive… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Jazz Pharmaceuticals financials

Famous investors that hold JAZZ

4 of the 50 well-known investors we track reported holding JAZZ in their latest 13F filing. The largest position is Ken Griffin's, worth $248M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.07M$248M0.1%+7%
Jim Simons · Renaissance TechnologiesQ3 2026483,573$112M0.2%-14%
Israel Englander · Millennium ManagementQ3 2026164,259$38M0.0%-78%
Ray Dalio · Bridgewater AssociatesQ3 2026145,155$33.6M0.1%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named JAZZ in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A8.6%
Nov 5, 2026FMR LLC13G/A8.6%

Questions about Jazz Pharmaceuticals plc (JAZZ) stock

Who owns the most JAZZ stock?

The largest reported owner of Jazz Pharmaceuticals plc (JAZZ) is BlackRock, Inc., with 9.5% of the company. In total, 641 funds and institutions reported holding JAZZ at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are JAZZ insiders buying or selling?

In the last 12 months, JAZZ insiders reported no open-market purchases and 67 sales worth $87.9M. The latest trade was on Nov 6, 2026. See every trade.

What is the short interest in JAZZ?

As of Oct 30, 2026, 5.80M JAZZ shares were sold short, 9.0% of the shares outstanding, down 1.1% from the report before. At the average daily volume of 755,707 shares, buying them all back would take about 7.7 trading days (days to cover). See the history.

Which famous investors hold JAZZ?

4 of the 50 well-known investors we track reported JAZZ in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $248M. See all holders.

Executive pay

Jazz Pharmaceuticals's chief executive was paid a total of $15.5M for the year ended Dec 31, 2024, up 1% from $15.3M the year before. In the last 12 months, Jazz Pharmaceuticals's executives and directors bought no stock on the open market and sold $87.9M.

Chief executive, total pay$15.5MYear ended Dec 31, 2024. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$17.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$4.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.